Exact Sciences Corp ( EXAS ) reported fourth-quarter financial results after the market close on Wednesday. Here’s a look at the key details from the quarter.

Q4 Earnings: Exact Sciences ( EXAS ) reported fourth-quarter revenue of $713 million, beating analyst estimates of $701.3 million, according to data from Benzinga Pro. Total revenue was up 10% on a year-over-year basis.

Screening revenue totaled $553 million in the quarter, up 14% year-over-year. Precision Oncology revenue came in at $161 million, up 0.4% year-over-year.

Exact Sciences ( EXAS ) generated $47 million of operating cash flow and $11 million of free cash flow during the quarter. The company ended the period with $1.04 billion in cash, cash equivalents and marketable securities.

“The Exact Sciences team is off to a good start in 2025, building on the momentum we created in the fourth quarter,” said Kevin Conroy, chairman and CEO of Exact Sciences ( EXAS ).

“This year is on track to be the most productive in company history, with continued execution from our core business and the launch of three innovative cancer tests. This will power years of growth and profitability, deepen our leadership in diagnostics, and help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment.”

Check This Out: Carvana Stock Hits The Brakes Following Q4 Earnings: Revenue Beat, EPS Beat, Upbeat Guidance — ‘This Is Just The Beginning’

Outlook: Exact Sciences ( EXAS ) expects full-year 2025 revenue to be in the range of $3.03 billion to $3.09 billion. Full-year Screening revenue is expected to be in the range of $2.35 billion to $2.39 billion, and Precision Oncology revenue is expected to be between $675 million and $695 million.

The company anticipates full-year adjusted EBITDA of $410 million to $440 million, versus $323 million in 2024.

Exact Sciences ( EXAS ) executives will further discuss the company’s quarterly results on a conference call set for 5 p.m. ET.

EXAS Price Action: Exact Sciences ( EXAS ) shares were down 2.2% after hours, trading at $49.36 at the time of publication Wednesday, according to Benzinga Pro.